Sarepta Therapeutics Inc (SRPT) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.

Total Revenue Chart for Sarepta Therapeutics Inc

Sarepta Therapeutics Inc (SRPT) revenue for FY2025 was USD 2.2B, a 15.6% change from FY2024. Sarepta Therapeutics Inc's revenue grew from USD 100.0K in 1995 to USD 2.2B in 2025 (2198137.0% over 30 years). Earnings per share moved from USD -0.11 in 2011 to USD -8.03 in 2022. Revenue compound annual growth rate: 5-year CAGR of 32.4%, 10-year CAGR of 111.1%, 20-year CAGR of 35.9%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.